Get started
ORYZON GENOMICS, S.A.ORYZON GENOMICS, S.A.ORYZON GENOMICS, S.A.

ORYZON GENOMICS, S.A.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ORY chart


Full chart

ORY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪208.88 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.060 EUR
Net income (FY)
‪−3.67 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪53.71 M‬
Beta (1Y)
0.37

About ORYZON GENOMICS, S.A.


Sector
Health Technology
Industry
Biotechnology
CEO
Carlos Manuel Buesa Arjol
Website
oryzon.com
Headquarters
Barcelona
Founded
2000
ISIN
ES0167733015
FIGI
BBG00BN8D1N0
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ORY news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ORY.

Frequently Asked Questions


The current price of ORY is 2.960 EUR — it has decreased by −3.92% in the past 24 hours. Watch ORYZON GENOMICS, S.A. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BME exchange ORYZON GENOMICS, S.A. stocks are traded under the ticker ORY.
ORY stock has fallen by −1.13% compared to the previous week, the month change is a 9.27% rise, over the last year ORYZON GENOMICS, S.A. has showed a 71.10% increase.
We've gathered analysts' opinions on ORYZON GENOMICS, S.A. future price: according to them, ORY price has a max estimate of 12.60 EUR and a min estimate of 4.00 EUR. Watch ORY chart and read a more detailed ORYZON GENOMICS, S.A. stock forecast: see what analysts think of ORYZON GENOMICS, S.A. and suggest that you do with its stocks.
ORY reached its all-time high on Dec 14, 2015 with the price of 5.250 EUR, and its all-time low was 1.400 EUR and was reached on Dec 31, 2024. View more price dynamics on ORY chart.
See other stocks reaching their highest and lowest prices.
ORY stock is 11.34% volatile and has beta coefficient of 0.37. Track ORYZON GENOMICS, S.A. stock price on the chart and check out the list of the most volatile stocks — is ORYZON GENOMICS, S.A. there?
Today ORYZON GENOMICS, S.A. has the market capitalization of ‪206.54 M‬, it has increased by 1.69% over the last week.
Yes, you can track ORYZON GENOMICS, S.A. financials in yearly and quarterly reports right on TradingView.
ORYZON GENOMICS, S.A. is going to release the next earnings report on May 2, 2025. Keep track of upcoming events with our Earnings Calendar.
ORY earnings for the last quarter are 0.00 EUR per share, whereas the estimation was −0.02 EUR resulting in a 99.22% surprise. The estimated earnings for the next quarter are −0.01 EUR per share. See more details about ORYZON GENOMICS, S.A. earnings.
ORYZON GENOMICS, S.A. revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ORY net income for the last quarter is ‪−1.39 M‬ EUR, while the quarter before that showed ‪−1.23 M‬ EUR of net income which accounts for −13.23% change. Track more ORYZON GENOMICS, S.A. financial stats to get the full picture.
No, ORY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ORY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORYZON GENOMICS, S.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORYZON GENOMICS, S.A. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORYZON GENOMICS, S.A. stock shows the buy signal. See more of ORYZON GENOMICS, S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.